ABOUT
ABOUT US
LEADERSHIP
Executive Team
MILESTONE
PRODUCT
ALL
Iron Deficiency Anemia
Emergency Care
Respiratory
PIPELINE
PIPELINE
Respiratory
Pain Management
Emergency Care
Iron Deficiency Anemia
PARTNERSHIP
NEWS
ALL
Press Releases
Strategic Cooperation Agreement with SHAPHAR
Nuance Pharma advances Rare Disease R&D with CORD
COPD新药 Ensifentrine 全球III期临床 ENHANCE-2 试验全解读
优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
Media
Nuance Pharma Closes Series D Financing
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
IND Approval for Respiratory Syncytial Virus (RSV) Vaccine in China
IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
RSV疫苗中国III期临床获批，呼吸特药精耕又一里程碑！
Partner News
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
BAVARIAN NORDIC ANNOUNCES GRANT OF PRIME ELIGIBILITY FROM THE EUROPEAN MEDICINES AGENCY FOR ITS RSV VACCINE CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS IN OLDER ADULTS
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
INVESTOR
CAREER
PROFILE
CONTACT